Abstract: The present invention is directed towards a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N-dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexanamine or a salt thereof (IIa) to produce Cariprazine (Ia) or a pharmaceutically acceptable salt thereof. The present invention is also directed towards amorphous form of Cariprazine hydrochloride (I) and solid dispersion of Cariprazine hydrochloride (I), and its preparation thereof.

Abstract: The present invention provides a process for the preparation of Docosanol (I). The process comprises reducing cis-13-Docosenoic acid (V) to obtain Docosanoic acid (III), which is further reduced to obtain Docosanol (I).

Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.

Abstract: A portable self-administrable medication delivery device with “End of Life” feature includes a housing, a drive member within said housing, a locking element and a medicine filled container. The device further provides a “Partial Dose Prevention” feature to deliver an accurate amount of dose with precision. The device is capable of delivering multiple doses of a liquid medicament contained therein without the need of priming the injector prior to administration and allows for repeated administration of a dose of medicament in a simple, easy, safe and accurate manner.

Abstract: The present invention relates to a process for the preparation of Tipiracil hydrochloride crystal III, which comprises reaction of Tipiracil with hydrochloric acid in presence of solvent is selected from alcohol and/or water. Further, the present invention relates to pure Tipiracil base having purity greater than about 99.0% by HPLC.

Abstract: The present invention relates to a process For the preparation of Dapagliflozin DL-Proline co-crystal and its use in the preparation/purification of Dapagliflozin. The invention also provides a process for the preparation of Dapagliflozin (R,S)-1.2-propanediol monohydrate.

Abstract: The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.

Abstract: The present invention provides an improved process for the preparation of Deferasirox of Formula-I substantially free from ‘hydrazino impurity’ by the condensation of 2-(2-hydrophenyl)-4H-1,3-benzoxazin-4-one of Formula-IV with 4-hydrazino benzoic acid of Formula-V in a polar solvent.

Abstract: The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.

Abstract: The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a process for the preparation of Docosanol (I). The process comprises reducing cis-13-Docosenoic acid (V) to obtain Docosanoic acid (III), which is further reduced to obtain Docosanol (I).

Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

Abstract: Device for immobilizing contents in a container and more particularly device and a method for immobilizing solid dosage forms such as pills, tablets, capsules or other breakable contents in containers are provided.

Abstract: The present invention relates to a process For the preparation of Dapagliflozin DL—Proline co-crystal and its use in the preparation/purification of Dapagliflozin. The invention also provides a process for the preparation of Dapagliflozin (R,S)-1.2-propanediol monohydrate.

Abstract: The present invention provides a process for the preparation of crystalline Lorcaserin hydrochloride hemihydrate of Formula (Ia), which comprises, Formula (Ia) (i) providing a solution of Lorcaserin base in a solvent; (ii) if water is present, removing water from the reaction mixture; (iii) adding hydrogen chloride to the reaction mixture; (iv) combining the reaction mixture with a suitable anti-solvent; and (v) isolating the crystalline Lorcaserin hydrochloride hemihydrate of Formula (Ia).

Abstract: The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a process for the preparation of ?-Form crystals of Mirabegron using a solvent selected from water.

Abstract: The present invention relates to a binder tree pharmaceutical composition comprising canagliflozin or a prodrug or a pharmaceutically acceptable salt thereof, and one or more 5 pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioequivalence profile to that of INVOKANA® tablets.

Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.

Abstract: Pharmaceutical compositions comprising an antidiabetic agent as an active agent are provided. The present invention relates to pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof as an active agent. The present invention also relates to process of preparation of pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising linagliptin to a subject in need thereof.